Diabetes Muddy Waters: Is It Type 1 or Type 2?

Description

The pathophysiology of diabetes is more complex than we thought, and it demands an evolved understanding. We’ve gone from an “ominous octet” of dysfunctional organ systems to the “egregious eleven,” with interplay among type 1, type 1.5, and type 2 diabetes. This means metformin alone cannot always achieve glycemic control for many patients. Clinicians initiating a second-line therapy must choose from several treatment options, including insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter 2 inhibitors. Attend this session to hear experts discuss unique treatment plans for patients with diabetes and learn how to identify the most appropriate adjunct therapies to control patients’ A1C and improve cardiovascular health.

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  1. Describe the eleven pathways that lead to hyperglycemia and how this impacts the diagnosis and treatment of diabetes.
  2. Discuss the new recommendations for antihyperglycemic therapy from the updated guidelines for type 2 diabetes.
  3. Compare the various non-insulin pharmacologic agents for the management of type 1 diabetes.
  4. Formulate a patient-centered diabetes treatment plan considering the A1C target, cardiovascular impact, and “egregious eleven.”
 
 
 
Speakers:
Susan
Susan Cornell, PharmD, BS, FAPhA
Associate Professor
Midwestern University
 
Kam
Kam Capoccia, BSPharm, PharmD, BCPS, CDE
Clinical Professor, Vice Chair of Practice and Advancement
Western New England Univeristy College of Pharmacy and Health Sciences
 
Learning Level: Level 2
Track: Pharmacist Clinical Patient Care Services, Ambulatory Care
Session Time Slot(s): 
Date: 
Friday, March 22
Time: 
8:00 AM - 10:00 AM
Room: 
Washington State Convention Center - Ballroom 6E
CEUs Pharmacist: .2
Activity Type:
Application-based